Related content

A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia

By Sarter Martin   Martinez Vicente   Kozak Rouba  

Psychopharmacology, Vol. 202, Iss. 1-3, 2009-01 ,pp. : 237-258

Springer Publishing Company

Access to resources Recommend Favorite

Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid

By Richardson A.J.   Easton T.   Puri B.K.  

European Neuropsychopharmacology, Vol. 10, Iss. 3, 2000-05 ,pp. : 189-193

Elsevier

Access to resources Recommend Favorite

Applying Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia to Achieve First Remission

By Liu Chen-Chung   Chiang Huey-Ling   Wu Szu-Ying  

CNS Drugs, Vol. 22, Iss. 3, 2008-01 ,pp. : 257-258

Adis International

Access to resources Recommend Favorite

Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

By Novick Diego   Haro Josep   Suarez David   Lambert Martin   Lépine Jean-Pierre   Naber Dieter  

Psychopharmacology, Vol. 191, Iss. 4, 2007-05 ,pp. : 1015-1022

Springer Publishing Company

Access to resources Recommend Favorite

The Concept of Salience Network Dysfunction in Schizophrenia: From Neuroimaging Observations to Therapeutic Opportunities

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 21, 2012-11 ,pp. : 2324-2338

Bentham Science Publishers

Access to resources Recommend Favorite